Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Inventiva announces design of LEGEND trial » 16:02
10/27/21
10/27
16:02
10/27/21
16:02
IVA

Inventiva

$14.90 /

+0.45 (+3.11%)

Inventiva announced the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IVA Inventiva
$14.90 /

+0.45 (+3.11%)

IVA Inventiva
$14.90 /

+0.45 (+3.11%)

09/22/21 H.C. Wainwright
Inventiva price target raised to $40 from $38 at H.C. Wainwright
05/04/21 Roth Capital
Inventiva price target raised to EUR 55 from EUR 46 at Roth Capital
03/08/21
Fly Intel: Top five analyst downgrades
03/08/21 Societe Generale
Societe Generale double downgrades Inventiva on delayed market entry
Over a month ago
Recommendations
Inventiva price target raised to $40 from $38 at H.C. Wainwright » 06:21
09/22/21
09/22
06:21
09/22/21
06:21
IVA

Inventiva

$14.13 /

-0.07 (-0.49%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Ed Arce raised the firm's price target on Inventiva to $40 from $38 and keeps a Buy rating on the shares. The analyst expects the NATiV3 trial to support lanifibranor's approval in the second half of 2025.

ShowHide Related Items >><<
IVA Inventiva
$14.13 /

-0.07 (-0.49%)

IVA Inventiva
$14.13 /

-0.07 (-0.49%)

05/04/21 Roth Capital
Inventiva price target raised to EUR 55 from EUR 46 at Roth Capital
03/08/21
Fly Intel: Top five analyst downgrades
03/08/21 Societe Generale
Societe Generale double downgrades Inventiva on delayed market entry
03/08/21 Societe Generale
Inventiva downgraded to Sell from Buy at Societe Generale
Hot Stocks
FDA extends prior fast track for lanifibranor for NASH to compensated cirrhosis » 16:09
09/21/21
09/21
16:09
09/21/21
16:09
IVA

Inventiva

$14.13 /

-0.07 (-0.49%)

Inventiva announced that…

Inventiva announced that the U.S. Food and Drug Administration, FDA, has decided that the Fast Track designation previously granted to lanifibranor in NASH encompasses the treatment of NASH patients with compensated cirrhosis. This decision follows a Fast Track designation request for lanifibranor in NASH with compensated cirrhosis filed by Inventiva with the FDA in August 2021. Previously, the FDA had granted both Fast Track and Breakthrough Therapy designations to lanifibranor for the treatment of NASH in September 2019 and October 2020, respectively. The FDA's dedicated Fast Track program is designed to facilitate the development and expedite the review and potential approval of drug candidates demonstrating the capacity to treat serious conditions and fill significant unmet medical needs.

ShowHide Related Items >><<
IVA Inventiva
$14.13 /

-0.07 (-0.49%)

05/04/21 Roth Capital
Inventiva price target raised to EUR 55 from EUR 46 at Roth Capital
03/08/21
Fly Intel: Top five analyst downgrades
03/08/21 Societe Generale
Societe Generale double downgrades Inventiva on delayed market entry
03/08/21 Societe Generale
Inventiva downgraded to Sell from Buy at Societe Generale
Over a quarter ago
Recommendations
Inventiva price target raised to EUR 55 from EUR 46 at Roth Capital » 09:58
05/04/21
05/04
09:58
05/04/21
09:58
IVA

Inventiva

/

+

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah raised the firm's price target on Inventiva (IVA) to EUR 55 from EUR 46 and keeps a Buy rating on the shares. AbbVie (ABBV), on its recent earnings call, announced that Cedirogant, an oral RORy inverse agonist developed in partnership with Inventiva, showed encouraging proof of concept efficacy to support advancement to a Phase 2b study. Jallah tells investors in a research note. The analyst believes the news is validating for Inventiva's platform and also financially rewarding since Inventiva is expected to receive another milestone payment upon Phase 2b study start.

ShowHide Related Items >><<
IVA Inventiva
/

+

IVA Inventiva
/

+

03/08/21
Fly Intel: Top five analyst downgrades
03/08/21 Societe Generale
Societe Generale double downgrades Inventiva on delayed market entry
03/08/21 Societe Generale
Inventiva downgraded to Sell from Buy at Societe Generale
10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
  • 10
    Jul
Downgrade
Fly Intel: Top five analyst downgrades » 09:55
03/08/21
03/08
09:55
03/08/21
09:55
VTRS

Viatris

$13.89 /

-0.05 (-0.36%)

, SEAS

SeaWorld

$50.50 /

+1.39 (+2.83%)

, IVA

Inventiva

$14.21 /

+ (+0.00%)

, ETR

Entergy

$89.09 /

-0.04 (-0.04%)

, HMST

HomeStreet

$47.06 /

+1.03 (+2.24%)

Catch up on today's…

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Viatris (VTRS) downgraded to Neutral from Buy at Goldman Sachs with analyst Nathan Rich saying he underappreciated the "magnitude and number of headwinds" facing the business in 2021. 2. SeaWorld (SEAS) downgraded to Neutral from Buy at Citi with analyst Jason Bazinet saying management continues to execute "remarkably well" with continued cost cuts, higher guest spending and initiatives like year-round park operations in several parks. 3. Inventiva (IVA) double downgraded to Sell from Buy at Societe Generale with analyst Delphine Le Louet saying after Phase II meetings with the oversight authorities, Inventiva will enter Phase III with its first patient. 4. Entergy (ETR) downgraded to Sector Weight from Overweight at KeyBanc with analyst Sophie Karp noting the company is now facing an additional proceeding at the FERC on top of the two existing complaints, and the regulatory climate in AR appears to grow more complicated. 5. HomeStreet (HMST) downgraded to Neutral from Buy at DA Davidson with analyst Jeff Rulis saying the company's recent progress is "not expected" to be "forfeited", but a "material" improvement from 2020's strong performance will be challenging over the near term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
VTRS Viatris
$13.89 /

-0.05 (-0.36%)

SEAS SeaWorld
$50.50 /

+1.39 (+2.83%)

IVA Inventiva
$14.21 /

+ (+0.00%)

HMST HomeStreet
$47.06 /

+1.03 (+2.24%)

ETR Entergy
$89.09 /

-0.04 (-0.04%)

VTRS Viatris
$13.89 /

-0.05 (-0.36%)

03/08/21 Goldman Sachs
Viatris downgraded to Neutral from Buy at Goldman Sachs
03/02/21 JPMorgan
Viatris downgraded to Neutral on 'modest' growth at JPMorgan
03/02/21 JPMorgan
Viatris downgraded to Neutral from Overweight at JPMorgan
02/26/21 Wolfe Research
Viatris downgraded to Peer Perform from Outperform at Wolfe Research
SEAS SeaWorld
$50.50 /

+1.39 (+2.83%)

03/08/21 B. Riley
SeaWorld price target raised to $65 from $53 at B. Riley Securities
03/08/21 Citi
SeaWorld downgraded to Neutral from Buy at Citi
03/01/21 KeyBanc
SeaWorld price target raised to $55 from $27 at KeyBanc
02/26/21 Truist
SeaWorld price target raised to $54 from $38 at Truist
IVA Inventiva
$14.21 /

+ (+0.00%)

03/08/21 Societe Generale
Societe Generale double downgrades Inventiva on delayed market entry
03/08/21 Societe Generale
Inventiva downgraded to Sell from Buy at Societe Generale
10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
ETR Entergy
$89.09 /

-0.04 (-0.04%)

03/08/21 KeyBanc
Entergy downgraded to Sector Weight at KeyBanc on growing regulatory concerns
03/08/21 KeyBanc
Entergy downgraded to Sector Weight from Overweight at KeyBanc
01/27/21 Mizuho
Entergy price target lowered to $105 from $110 at Mizuho
01/21/21 Evercore ISI
Entergy upgraded to Outperform from In Line at Evercore ISI
HMST HomeStreet
$47.06 /

+1.03 (+2.24%)

03/08/21 DA Davidson
HomeStreet downgraded to Neutral from Buy at DA Davidson
03/08/21 DA Davidson
HomeStreet downgraded to Neutral from Buy at DA Davidson
01/27/21 B. Riley
HomeStreet price target raised to $48 from $42 at B. Riley Securities
01/07/21 B. Riley
HomeStreet price target raised to $42 from $40 at B. Riley Securities
VTRS Viatris
$13.89 /

-0.05 (-0.36%)

SEAS SeaWorld
$50.50 /

+1.39 (+2.83%)

HMST HomeStreet
$47.06 /

+1.03 (+2.24%)

ETR Entergy
$89.09 /

-0.04 (-0.04%)

  • 10
    Jul
SEAS SeaWorld
$50.50 /

+1.39 (+2.83%)

SEAS SeaWorld
$50.50 /

+1.39 (+2.83%)

IVA Inventiva
$14.21 /

+ (+0.00%)

VTRS Viatris
$13.89 /

-0.05 (-0.36%)

SEAS SeaWorld
$50.50 /

+1.39 (+2.83%)

Downgrade
Societe Generale double downgrades Inventiva on delayed market entry » 07:02
03/08/21
03/08
07:02
03/08/21
07:02
IVA

Inventiva

$14.21 /

-0.29 (-2.00%)

Societe Generale analyst…

Societe Generale analyst Delphine Le Louet double downgraded Inventiva to Sell from Buy with a price target of EUR 9.30, down from EUR 22. Inventiva is a French biotech with a major asset in late-stage development in nonalcoholic steatosis hepatitis, Le Louet tells investors in a research note. After Phase II meetings with the oversight authorities, Inventiva will enter Phase III with its first patient, says the analyst. Le Louet expects this to take place in Q3, or six months later than originally thought. This has an immediate impact on the expected date of market entry, which is now seen in 2025 versus late 2023 previously, says Le Louet.

ShowHide Related Items >><<
IVA Inventiva
$14.21 /

-0.29 (-2.00%)

IVA Inventiva
$14.21 /

-0.29 (-2.00%)

03/08/21 Societe Generale
Inventiva downgraded to Sell from Buy at Societe Generale
10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
  • 10
    Jul
IVA Inventiva
$14.21 /

-0.29 (-2.00%)

Downgrade
Inventiva downgraded to Sell from Buy at Societe Generale » 05:46
03/08/21
03/08
05:46
03/08/21
05:46
IVA

Inventiva

$14.21 /

-0.29 (-2.00%)

Societe Generale analyst…

Societe Generale analyst Delphine Le Louet double downgraded Inventiva to Sell from Buy with a EUR 9.30 price target.

ShowHide Related Items >><<
IVA Inventiva
$14.21 /

-0.29 (-2.00%)

IVA Inventiva
$14.21 /

-0.29 (-2.00%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
  • 10
    Jul
IVA Inventiva
$14.21 /

-0.29 (-2.00%)

Conference/Events
Credit Suisse to hold a virtual conference » 04:55
03/04/21
03/04
04:55
03/04/21
04:55
ABC

AmerisourceBergen

$103.35 /

-0.82 (-0.79%)

, AFMD

Affimed

$5.60 /

-0.07 (-1.23%)

, AMED

Amedisys

$241.61 /

-11.92 (-4.70%)

, AZN

AstraZeneca

$47.17 /

-0.55 (-1.15%)

, BNTX

BioNTech

$97.43 /

-7.43 (-7.09%)

, CSL

Carlisle

$147.55 /

-2.92 (-1.94%)

, CVAC

CureVac

$83.44 /

-9.76 (-10.47%)

, FMS

Fresenius Medical

$34.71 /

-0.615 (-1.74%)

, GLPG

Galapagos

$82.20 /

-2.63 (-3.10%)

, GLTO

Galecto

$9.90 /

-0.45 (-4.35%)

, GSK

GlaxoSmithKline

$34.24 /

+0.15 (+0.44%)

, IVA

Inventiva

$15.00 /

-1.9 (-11.24%)

, IPSEY

Ipsen

$0.00 /

+ (+0.00%)

, LNTH

Lantheus

$18.45 /

+0.08 (+0.44%)

, NOV

NOV Inc.

$15.03 /

+0.04 (+0.27%)

, NOVO

Novo Group Inc

$0.00 /

+ (+0.00%)

, NVS

Novartis

$87.54 /

-0.635 (-0.72%)

, PHG

Philips

$54.00 /

-1.23 (-2.23%)

, SNY

Sanofi

$45.46 /

-0.495 (-1.08%)

, TAK

Takeda Pharmaceutical

$17.70 /

+0.45 (+2.61%)

, ZEAL

Zealand Pharma

$31.52 /

-1.44 (-4.37%)

2021 London Global…

2021 London Global Healthcare Virtual Conference will be held on March 2-4. Webcast Link

ShowHide Related Items >><<
ZEAL Zealand Pharma
$31.52 /

-1.44 (-4.37%)

TAK Takeda Pharmaceutical
$17.70 /

+0.45 (+2.61%)

SNY Sanofi
$45.46 /

-0.495 (-1.08%)

PHG Philips
$54.00 /

-1.23 (-2.23%)

NVS Novartis
$87.54 /

-0.635 (-0.72%)

NOV NOV Inc.
$15.03 /

+0.04 (+0.27%)

LNTH Lantheus
$18.45 /

+0.08 (+0.44%)

IVA Inventiva
$15.00 /

-1.9 (-11.24%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$34.24 /

+0.15 (+0.44%)

GLTO Galecto
$9.90 /

-0.45 (-4.35%)

GLPG Galapagos
$82.20 /

-2.63 (-3.10%)

FMS Fresenius Medical
$34.71 /

-0.615 (-1.74%)

CVAC CureVac
$83.44 /

-9.76 (-10.47%)

CSL Carlisle
$147.55 /

-2.92 (-1.94%)

BNTX BioNTech
$97.43 /

-7.43 (-7.09%)

AZN AstraZeneca
$47.17 /

-0.55 (-1.15%)

AMED Amedisys
$241.61 /

-11.92 (-4.70%)

AFMD Affimed
$5.60 /

-0.07 (-1.23%)

ABC AmerisourceBergen
$103.35 /

-0.82 (-0.79%)

ABC AmerisourceBergen
$103.35 /

-0.82 (-0.79%)

02/09/21 Mizuho
AmerisourceBergen price target raised to $114 from $104 at Mizuho
02/08/21 Cowen
AmerisourceBergen price target raised to $150 from $145 at Cowen
02/04/21 Evercore ISI
AmerisourceBergen upgraded to Outperform after Q1 report at Evercore ISI
02/04/21 Evercore ISI
AmerisourceBergen upgraded to Outperform from In Line at Evercore ISI
AFMD Affimed
$5.60 /

-0.07 (-1.23%)

AMED Amedisys
$241.61 /

-11.92 (-4.70%)

02/23/21 Benchmark
Amedisys price target raised to $325 from $275 at Benchmark
02/08/21 Deutsche Bank
Amedisys price target raised to $340 from $275 at Deutsche Bank
01/05/21 Truist
Amedisys price target raised to $325 from $280 at Truist
11/03/20 Barclays
Amedisys price target raised to $298 from $290 at Barclays
AZN AstraZeneca
$47.17 /

-0.55 (-1.15%)

02/25/21
Fly Intel: Top five analyst upgrades
02/25/21 UBS
AstraZeneca upgraded to Buy from Neutral at UBS
02/04/21 Piper Sandler
Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler
02/01/21 BofA
BofA downgrades Moderna to Underperform, sees shares priced for 'best-case'
BNTX BioNTech
$97.43 /

-7.43 (-7.09%)

02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
01/29/21 Piper Sandler
Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
CSL Carlisle
$147.55 /

-2.92 (-1.94%)

01/26/21 Longbow
Carlisle price target raised to $160 from $150 at Longbow
01/08/21 Oppenheimer
Carlisle price target raised to $175 from $160 at Oppenheimer
11/13/20
Carlisle cut to Hold at Loop Capital on valuation
11/13/20 Loop Capital
Carlisle downgraded to Hold from Buy at Loop Capital
CVAC CureVac
$83.44 /

-9.76 (-10.47%)

01/07/21 Morgan Stanley
CureVac COVID-19 deal provides 'sentiment boost' for Bayer, says Morgan Stanley
12/10/20 Credit Suisse
CureVac downgraded to Underperform on rising valuation at Credit Suisse
12/10/20 Credit Suisse
CureVac downgraded to Underperform from Neutral at Credit Suisse
11/02/20 Piper Sandler
CureVac's positive vaccine data bodes well for Arcturus's ARCT-021, says Piper
FMS Fresenius Medical
$34.71 /

-0.615 (-1.74%)

03/02/21 Berenberg
Fresenius Medical price target lowered to EUR 79.50 from EUR 80.40 at Berenberg
02/26/21 JPMorgan
Fresenius Medical price target raised to EUR 52.40 from EUR 51.10 at JPMorgan
02/24/21 Truist
Fresenius Medical cut to Hold at Truist on more difficult operating backdrop
02/24/21 Truist
Fresenius Medical downgraded to Hold from Buy at Truist
GLPG Galapagos
$82.20 /

-2.63 (-3.10%)

03/02/21 Barclays
Galapagos price target lowered to EUR 69 from EUR 85.50 at Barclays
02/23/21 BofA
Galapagos upgraded to Neutral from Underperform at BofA
02/23/21 BofA
Galapagos upgraded to Neutral from Underperform at BofA
02/19/21 Raymond James
Raymond James upgrades 'heavily discounted' Galapagos to Outperform
GLTO Galecto
$9.90 /

-0.45 (-4.35%)

11/23/20 SVB Leerink
SVB Leerink bullish on Galecto, initiates with an Outperform
11/23/20 SVB Leerink
Galecto initiated with an Outperform at SVB Leerink
11/23/20 Credit Suisse
Galecto initiated with an Outperform at Credit Suisse
11/23/20 BofA
Galecto initiated with a Buy at BofA
GSK GlaxoSmithKline
$34.24 /

+0.15 (+0.44%)

03/03/21 H.C. Wainwright
Vir Biotechnology selloff a 'terrific buying opportunity,' says H.C. Wainwright
02/12/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,580 GBp at Morgan Stanley
02/11/21 Berenberg
GlaxoSmithKline price target lowered to 1,570 GBp from 1,720 GBp at Berenberg
02/09/21 JPMorgan
GlaxoSmithKline price target lowered to 1,300 GBp from 1,500 GBp at JPMorgan
IVA Inventiva
$15.00 /

-1.9 (-11.24%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
IPSEY Ipsen
$0.00 /

+ (+0.00%)

02/16/21 Barclays
Ipsen price target lowered to EUR 89 from EUR 96 at Barclays
01/14/21 Societe Generale
Ipsen upgraded to Buy from Hold at Societe Generale
12/08/20 Morgan Stanley
Ipsen downgraded to Equal Weight from Overweight at Morgan Stanley
12/04/20 BofA
Ipsen downgraded to Neutral from Buy at BofA
LNTH Lantheus
$18.45 /

+0.08 (+0.44%)

02/01/21
Fly Intel: Top five analyst initiations
02/01/21 SVB Leerink
SVB Leerink bullish on Lantheus, initiates with an Outperform
02/01/21 SVB Leerink
Lantheus initiated with an Outperform at SVB Leerink
12/29/20 Credit Suisse
Lantheus price target lowered to $14 from $16 at Credit Suisse
NOV NOV Inc.
$15.03 /

+0.04 (+0.27%)

01/21/21 Susquehanna
NOV Inc. price target lowered to $17 from $18 at Susquehanna
01/21/21 Wells Fargo
NOV Inc. upgraded to Overweight from Equal Weight at Wells Fargo
01/21/21 Wells Fargo
NOV Inc. upgraded to Overweight from Equal Weight at Wells Fargo
01/12/21 Citi
NOV Inc. upgraded to Buy from Neutral at Citi
NOVO Novo Group Inc
$0.00 /

+ (+0.00%)

NVS Novartis
$87.54 /

-0.635 (-0.72%)

03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
02/02/21 Morgan Stanley
Novartis price target lowered to CHF 102 from CHF 104 at Morgan Stanley
02/01/21 Truist
iRhythm price target lowered to $220 from $265 at Truist
02/01/21 Cowen
Novartis downgraded to Market Perform after 'tepid' guidance at Cowen
PHG Philips
$54.00 /

-1.23 (-2.23%)

01/26/21 Credit Suisse
Philips price target raised to EUR 45 from EUR 41 at Credit Suisse
01/26/21 JPMorgan
Philips price target raised to EUR 44.90 from EUR 44 at JPMorgan
01/26/21 UBS
Philips price target raised to EUR 54 from EUR 51 at UBS
01/25/21 Morgan Stanley
iRhythm price target raised to $288 from $227 at Morgan Stanley
SNY Sanofi
$45.46 /

-0.495 (-1.08%)

02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
02/10/21 Morgan Stanley
Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
01/19/21 UBS
Sanofi price target lowered to EUR 99 from EUR 100 at UBS
TAK Takeda Pharmaceutical
$17.70 /

+0.45 (+2.61%)

03/03/21 RBC Capital
Ovid downgraded to Sector Perform at RBC Capital after rally on Takeda deal
01/29/21 Morgan Stanley
Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout
12/29/20 Needham
Needham names Phathom Pharmaceuticals Top Pick for 2021
12/15/20 Needham
Phathom Pharmaceuticals price target raised to $55 from $45 at Needham
ZEAL Zealand Pharma
$31.52 /

-1.44 (-4.37%)

03/10/20 Morgan Stanley
Zealand Pharma EPS estimates cut at Morgan Stanley
ZEAL Zealand Pharma
$31.52 /

-1.44 (-4.37%)

SNY Sanofi
$45.46 /

-0.495 (-1.08%)

PHG Philips
$54.00 /

-1.23 (-2.23%)

NVS Novartis
$87.54 /

-0.635 (-0.72%)

NOV NOV Inc.
$15.03 /

+0.04 (+0.27%)

LNTH Lantheus
$18.45 /

+0.08 (+0.44%)

GSK GlaxoSmithKline
$34.24 /

+0.15 (+0.44%)

GLTO Galecto
$9.90 /

-0.45 (-4.35%)

GLPG Galapagos
$82.20 /

-2.63 (-3.10%)

CSL Carlisle
$147.55 /

-2.92 (-1.94%)

AZN AstraZeneca
$47.17 /

-0.55 (-1.15%)

AMED Amedisys
$241.61 /

-11.92 (-4.70%)

ABC AmerisourceBergen
$103.35 /

-0.82 (-0.79%)

  • 28
    Jan
  • 13
    Jan
  • 29
    Oct
  • 14
    Aug
  • 23
    Jul
  • 10
    Jul
TAK Takeda Pharmaceutical
$17.70 /

+0.45 (+2.61%)

SNY Sanofi
$45.46 /

-0.495 (-1.08%)

PHG Philips
$54.00 /

-1.23 (-2.23%)

NVS Novartis
$87.54 /

-0.635 (-0.72%)

GSK GlaxoSmithKline
$34.24 /

+0.15 (+0.44%)

FMS Fresenius Medical
$34.71 /

-0.615 (-1.74%)

CVAC CureVac
$83.44 /

-9.76 (-10.47%)

BNTX BioNTech
$97.43 /

-7.43 (-7.09%)

AZN AstraZeneca
$47.17 /

-0.55 (-1.15%)

ABC AmerisourceBergen
$103.35 /

-0.82 (-0.79%)

TAK Takeda Pharmaceutical
$17.70 /

+0.45 (+2.61%)

SNY Sanofi
$45.46 /

-0.495 (-1.08%)

PHG Philips
$54.00 /

-1.23 (-2.23%)

NVS Novartis
$87.54 /

-0.635 (-0.72%)

NOV NOV Inc.
$15.03 /

+0.04 (+0.27%)

LNTH Lantheus
$18.45 /

+0.08 (+0.44%)

IVA Inventiva
$15.00 /

-1.9 (-11.24%)

GSK GlaxoSmithKline
$34.24 /

+0.15 (+0.44%)

GLTO Galecto
$9.90 /

-0.45 (-4.35%)

GLPG Galapagos
$82.20 /

-2.63 (-3.10%)

CVAC CureVac
$83.44 /

-9.76 (-10.47%)

BNTX BioNTech
$97.43 /

-7.43 (-7.09%)

AZN AstraZeneca
$47.17 /

-0.55 (-1.15%)

AMED Amedisys
$241.61 /

-11.92 (-4.70%)

ABC AmerisourceBergen
$103.35 /

-0.82 (-0.79%)

TAK Takeda Pharmaceutical
$17.70 /

+0.45 (+2.61%)

NOV NOV Inc.
$15.03 /

+0.04 (+0.27%)

GSK GlaxoSmithKline
$34.24 /

+0.15 (+0.44%)

CVAC CureVac
$83.44 /

-9.76 (-10.47%)

BNTX BioNTech
$97.43 /

-7.43 (-7.09%)

AZN AstraZeneca
$47.17 /

-0.55 (-1.15%)

ABC AmerisourceBergen
$103.35 /

-0.82 (-0.79%)

Conference/Events
Credit Suisse to hold a virtual conference » 04:55
03/03/21
03/03
04:55
03/03/21
04:55
ABC

AmerisourceBergen

$104.30 /

+1.22 (+1.18%)

, AFMD

Affimed

$5.67 /

-0.24 (-4.06%)

, AMED

Amedisys

$252.16 /

-2.56 (-1.01%)

, AZN

AstraZeneca

$47.72 /

-0.38 (-0.79%)

, BNTX

BioNTech

$104.98 /

-5 (-4.55%)

, CSL

Carlisle

$150.47 /

+2.445 (+1.65%)

, CVAC

CureVac

$93.20 /

-2.98 (-3.10%)

, FMS

Fresenius Medical

$35.31 /

+0.26 (+0.74%)

, GLPG

Galapagos

$84.42 /

-0.23 (-0.27%)

, GLTO

Galecto

$10.35 /

-0.46 (-4.26%)

, GSK

GlaxoSmithKline

$34.10 /

+0.355 (+1.05%)

, IVA

Inventiva

$16.90 /

+ (+0.00%)

, IPSEY

Ipsen

$0.00 /

+ (+0.00%)

, LNTH

Lantheus

$18.32 /

-0.7 (-3.68%)

, NOV

NOV Inc.

$14.99 /

-0.655 (-4.19%)

, NOVO

Novo Group Inc

$0.00 /

+ (+0.00%)

, NVS

Novartis

$88.17 /

+0.73 (+0.83%)

, PHG

Philips

$55.23 /

+0.19 (+0.35%)

, SNY

Sanofi

$45.95 /

+0.07 (+0.15%)

, TAK

Takeda Pharmaceutical

$17.25 /

+0.28 (+1.65%)

, ZEAL

Zealand Pharma

$33.38 /

+0.67 (+2.05%)

2021 London Global…

2021 London Global Healthcare Virtual Conference will be held on March 2-4. Webcast Link

ShowHide Related Items >><<
ZEAL Zealand Pharma
$33.38 /

+0.67 (+2.05%)

TAK Takeda Pharmaceutical
$17.25 /

+0.28 (+1.65%)

SNY Sanofi
$45.95 /

+0.07 (+0.15%)

PHG Philips
$55.23 /

+0.19 (+0.35%)

NVS Novartis
$88.17 /

+0.73 (+0.83%)

NOV NOV Inc.
$14.99 /

-0.655 (-4.19%)

LNTH Lantheus
$18.32 /

-0.7 (-3.68%)

IVA Inventiva
$16.90 /

+ (+0.00%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$34.10 /

+0.355 (+1.05%)

GLTO Galecto
$10.35 /

-0.46 (-4.26%)

GLPG Galapagos
$84.42 /

-0.23 (-0.27%)

FMS Fresenius Medical
$35.31 /

+0.26 (+0.74%)

CVAC CureVac
$93.20 /

-2.98 (-3.10%)

CSL Carlisle
$150.47 /

+2.445 (+1.65%)

BNTX BioNTech
$104.98 /

-5 (-4.55%)

AZN AstraZeneca
$47.72 /

-0.38 (-0.79%)

AMED Amedisys
$252.16 /

-2.56 (-1.01%)

AFMD Affimed
$5.67 /

-0.24 (-4.06%)

ABC AmerisourceBergen
$104.30 /

+1.22 (+1.18%)

ABC AmerisourceBergen
$104.30 /

+1.22 (+1.18%)

02/09/21 Mizuho
AmerisourceBergen price target raised to $114 from $104 at Mizuho
02/08/21 Cowen
AmerisourceBergen price target raised to $150 from $145 at Cowen
02/04/21 Evercore ISI
AmerisourceBergen upgraded to Outperform after Q1 report at Evercore ISI
02/04/21 Evercore ISI
AmerisourceBergen upgraded to Outperform from In Line at Evercore ISI
AFMD Affimed
$5.67 /

-0.24 (-4.06%)

AMED Amedisys
$252.16 /

-2.56 (-1.01%)

02/23/21 Benchmark
Amedisys price target raised to $325 from $275 at Benchmark
02/08/21 Deutsche Bank
Amedisys price target raised to $340 from $275 at Deutsche Bank
01/05/21 Truist
Amedisys price target raised to $325 from $280 at Truist
11/03/20 Barclays
Amedisys price target raised to $298 from $290 at Barclays
AZN AstraZeneca
$47.72 /

-0.38 (-0.79%)

02/25/21
Fly Intel: Top five analyst upgrades
02/25/21 UBS
AstraZeneca upgraded to Buy from Neutral at UBS
02/04/21 Piper Sandler
Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler
02/01/21 BofA
BofA downgrades Moderna to Underperform, sees shares priced for 'best-case'
BNTX BioNTech
$104.98 /

-5 (-4.55%)

02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
01/29/21 Piper Sandler
Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
CSL Carlisle
$150.47 /

+2.445 (+1.65%)

01/26/21 Longbow
Carlisle price target raised to $160 from $150 at Longbow
01/08/21 Oppenheimer
Carlisle price target raised to $175 from $160 at Oppenheimer
11/13/20
Carlisle cut to Hold at Loop Capital on valuation
11/13/20 Loop Capital
Carlisle downgraded to Hold from Buy at Loop Capital
CVAC CureVac
$93.20 /

-2.98 (-3.10%)

01/07/21 Morgan Stanley
CureVac COVID-19 deal provides 'sentiment boost' for Bayer, says Morgan Stanley
12/10/20 Credit Suisse
CureVac downgraded to Underperform on rising valuation at Credit Suisse
12/10/20 Credit Suisse
CureVac downgraded to Underperform from Neutral at Credit Suisse
11/02/20 Piper Sandler
CureVac's positive vaccine data bodes well for Arcturus's ARCT-021, says Piper
FMS Fresenius Medical
$35.31 /

+0.26 (+0.74%)

03/02/21 Berenberg
Fresenius Medical price target lowered to EUR 79.50 from EUR 80.40 at Berenberg
02/26/21 JPMorgan
Fresenius Medical price target raised to EUR 52.40 from EUR 51.10 at JPMorgan
02/24/21 Truist
Fresenius Medical cut to Hold at Truist on more difficult operating backdrop
02/24/21 Truist
Fresenius Medical downgraded to Hold from Buy at Truist
GLPG Galapagos
$84.42 /

-0.23 (-0.27%)

03/02/21 Barclays
Galapagos price target lowered to EUR 69 from EUR 85.50 at Barclays
02/23/21 BofA
Galapagos upgraded to Neutral from Underperform at BofA
02/23/21 BofA
Galapagos upgraded to Neutral from Underperform at BofA
02/19/21 Raymond James
Raymond James upgrades 'heavily discounted' Galapagos to Outperform
GLTO Galecto
$10.35 /

-0.46 (-4.26%)

11/23/20 SVB Leerink
SVB Leerink bullish on Galecto, initiates with an Outperform
11/23/20 SVB Leerink
Galecto initiated with an Outperform at SVB Leerink
11/23/20 Credit Suisse
Galecto initiated with an Outperform at Credit Suisse
11/23/20 BofA
Galecto initiated with a Buy at BofA
GSK GlaxoSmithKline
$34.10 /

+0.355 (+1.05%)

02/12/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,580 GBp at Morgan Stanley
02/11/21 Berenberg
GlaxoSmithKline price target lowered to 1,570 GBp from 1,720 GBp at Berenberg
02/09/21 JPMorgan
GlaxoSmithKline price target lowered to 1,300 GBp from 1,500 GBp at JPMorgan
02/08/21 UBS
GlaxoSmithKline price target lowered to 1,320 GBp from 1,450 GBp at UBS
IVA Inventiva
$16.90 /

+ (+0.00%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
IPSEY Ipsen
$0.00 /

+ (+0.00%)

02/16/21 Barclays
Ipsen price target lowered to EUR 89 from EUR 96 at Barclays
01/14/21 Societe Generale
Ipsen upgraded to Buy from Hold at Societe Generale
12/08/20 Morgan Stanley
Ipsen downgraded to Equal Weight from Overweight at Morgan Stanley
12/04/20 BofA
Ipsen downgraded to Neutral from Buy at BofA
LNTH Lantheus
$18.32 /

-0.7 (-3.68%)

02/01/21
Fly Intel: Top five analyst initiations
02/01/21 SVB Leerink
SVB Leerink bullish on Lantheus, initiates with an Outperform
02/01/21 SVB Leerink
Lantheus initiated with an Outperform at SVB Leerink
12/29/20 Credit Suisse
Lantheus price target lowered to $14 from $16 at Credit Suisse
NOV NOV Inc.
$14.99 /

-0.655 (-4.19%)

01/21/21 Susquehanna
NOV Inc. price target lowered to $17 from $18 at Susquehanna
01/21/21 Wells Fargo
NOV Inc. upgraded to Overweight from Equal Weight at Wells Fargo
01/21/21 Wells Fargo
NOV Inc. upgraded to Overweight from Equal Weight at Wells Fargo
01/12/21 Citi
NOV Inc. upgraded to Buy from Neutral at Citi
NOVO Novo Group Inc
$0.00 /

+ (+0.00%)

NVS Novartis
$88.17 /

+0.73 (+0.83%)

03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
02/02/21 Morgan Stanley
Novartis price target lowered to CHF 102 from CHF 104 at Morgan Stanley
02/01/21 Truist
iRhythm price target lowered to $220 from $265 at Truist
02/01/21 Cowen
Novartis downgraded to Market Perform after 'tepid' guidance at Cowen
PHG Philips
$55.23 /

+0.19 (+0.35%)

01/26/21 Credit Suisse
Philips price target raised to EUR 45 from EUR 41 at Credit Suisse
01/26/21 JPMorgan
Philips price target raised to EUR 44.90 from EUR 44 at JPMorgan
01/26/21 UBS
Philips price target raised to EUR 54 from EUR 51 at UBS
01/25/21 Morgan Stanley
iRhythm price target raised to $288 from $227 at Morgan Stanley
SNY Sanofi
$45.95 /

+0.07 (+0.15%)

02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
02/10/21 Morgan Stanley
Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
01/19/21 UBS
Sanofi price target lowered to EUR 99 from EUR 100 at UBS
TAK Takeda Pharmaceutical
$17.25 /

+0.28 (+1.65%)

01/29/21 Morgan Stanley
Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout
12/29/20 Needham
Needham names Phathom Pharmaceuticals Top Pick for 2021
12/15/20 Needham
Phathom Pharmaceuticals price target raised to $55 from $45 at Needham
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
ZEAL Zealand Pharma
$33.38 /

+0.67 (+2.05%)

03/10/20 Morgan Stanley
Zealand Pharma EPS estimates cut at Morgan Stanley
ZEAL Zealand Pharma
$33.38 /

+0.67 (+2.05%)

SNY Sanofi
$45.95 /

+0.07 (+0.15%)

PHG Philips
$55.23 /

+0.19 (+0.35%)

NVS Novartis
$88.17 /

+0.73 (+0.83%)

NOV NOV Inc.
$14.99 /

-0.655 (-4.19%)

LNTH Lantheus
$18.32 /

-0.7 (-3.68%)

GSK GlaxoSmithKline
$34.10 /

+0.355 (+1.05%)

GLTO Galecto
$10.35 /

-0.46 (-4.26%)

GLPG Galapagos
$84.42 /

-0.23 (-0.27%)

CSL Carlisle
$150.47 /

+2.445 (+1.65%)

AZN AstraZeneca
$47.72 /

-0.38 (-0.79%)

AMED Amedisys
$252.16 /

-2.56 (-1.01%)

ABC AmerisourceBergen
$104.30 /

+1.22 (+1.18%)

  • 28
    Jan
  • 13
    Jan
  • 29
    Oct
  • 14
    Aug
  • 23
    Jul
  • 10
    Jul
TAK Takeda Pharmaceutical
$17.25 /

+0.28 (+1.65%)

SNY Sanofi
$45.95 /

+0.07 (+0.15%)

PHG Philips
$55.23 /

+0.19 (+0.35%)

NVS Novartis
$88.17 /

+0.73 (+0.83%)

GSK GlaxoSmithKline
$34.10 /

+0.355 (+1.05%)

FMS Fresenius Medical
$35.31 /

+0.26 (+0.74%)

CVAC CureVac
$93.20 /

-2.98 (-3.10%)

BNTX BioNTech
$104.98 /

-5 (-4.55%)

AZN AstraZeneca
$47.72 /

-0.38 (-0.79%)

ABC AmerisourceBergen
$104.30 /

+1.22 (+1.18%)

SNY Sanofi
$45.95 /

+0.07 (+0.15%)

PHG Philips
$55.23 /

+0.19 (+0.35%)

NVS Novartis
$88.17 /

+0.73 (+0.83%)

NOV NOV Inc.
$14.99 /

-0.655 (-4.19%)

LNTH Lantheus
$18.32 /

-0.7 (-3.68%)

IVA Inventiva
$16.90 /

+ (+0.00%)

GSK GlaxoSmithKline
$34.10 /

+0.355 (+1.05%)

GLTO Galecto
$10.35 /

-0.46 (-4.26%)

GLPG Galapagos
$84.42 /

-0.23 (-0.27%)

CVAC CureVac
$93.20 /

-2.98 (-3.10%)

BNTX BioNTech
$104.98 /

-5 (-4.55%)

AZN AstraZeneca
$47.72 /

-0.38 (-0.79%)

AMED Amedisys
$252.16 /

-2.56 (-1.01%)

ABC AmerisourceBergen
$104.30 /

+1.22 (+1.18%)

TAK Takeda Pharmaceutical
$17.25 /

+0.28 (+1.65%)

NOV NOV Inc.
$14.99 /

-0.655 (-4.19%)

GSK GlaxoSmithKline
$34.10 /

+0.355 (+1.05%)

CVAC CureVac
$93.20 /

-2.98 (-3.10%)

BNTX BioNTech
$104.98 /

-5 (-4.55%)

AZN AstraZeneca
$47.72 /

-0.38 (-0.79%)

ABC AmerisourceBergen
$104.30 /

+1.22 (+1.18%)

Conference/Events
Credit Suisse to hold a virtual conference » 09:17
03/02/21
03/02
09:17
03/02/21
09:17
ABC

AmerisourceBergen

$103.12 /

+1.88 (+1.86%)

, AFMD

Affimed

$5.91 /

+0.25 (+4.42%)

, AMED

Amedisys

$254.74 /

+0.61 (+0.24%)

, AZN

AstraZeneca

$48.10 /

-0.25 (-0.52%)

, BNTX

BioNTech

$110.06 /

+0.61 (+0.56%)

, CSL

Carlisle

$148.03 /

+2.725 (+1.88%)

, CVAC

CureVac

$96.15 /

+1.39 (+1.47%)

, FMS

Fresenius Medical

$35.05 /

+0.49 (+1.42%)

, GLPG

Galapagos

$84.65 /

+1.6 (+1.93%)

, GLTO

Galecto

$10.81 /

+0.5301 (+5.16%)

, GSK

GlaxoSmithKline

$33.74 /

+0.13 (+0.39%)

, IVA

Inventiva

$16.90 /

+1.9 (+12.67%)

, IPSEY

Ipsen

$0.00 /

+ (+0.00%)

, LNTH

Lantheus

$19.06 /

+0.33 (+1.76%)

, NOV

NOV Inc.

$15.65 /

+0.525 (+3.47%)

, NOVO

Novo Group Inc

$0.00 /

+ (+0.00%)

, NVS

Novartis

$87.44 /

+1.42 (+1.65%)

, PHG

Philips

$55.04 /

+0.54 (+0.99%)

, SNY

Sanofi

$45.90 /

+0.015 (+0.03%)

, TAK

Takeda Pharmaceutical

$16.97 /

+0.26 (+1.56%)

, ZEAL

Zealand Pharma

$32.71 /

+0.76 (+2.38%)

2021 London Global…

2021 London Global Healthcare Virtual Conference will be held on March 2-4. Webcast Link

ShowHide Related Items >><<
ZEAL Zealand Pharma
$32.71 /

+0.76 (+2.38%)

TAK Takeda Pharmaceutical
$16.97 /

+0.26 (+1.56%)

SNY Sanofi
$45.90 /

+0.015 (+0.03%)

PHG Philips
$55.04 /

+0.54 (+0.99%)

NVS Novartis
$87.44 /

+1.42 (+1.65%)

NOV NOV Inc.
$15.65 /

+0.525 (+3.47%)

LNTH Lantheus
$19.06 /

+0.33 (+1.76%)

IVA Inventiva
$16.90 /

+1.9 (+12.67%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$33.74 /

+0.13 (+0.39%)

GLTO Galecto
$10.81 /

+0.5301 (+5.16%)

GLPG Galapagos
$84.65 /

+1.6 (+1.93%)

FMS Fresenius Medical
$35.05 /

+0.49 (+1.42%)

CVAC CureVac
$96.15 /

+1.39 (+1.47%)

CSL Carlisle
$148.03 /

+2.725 (+1.88%)

BNTX BioNTech
$110.06 /

+0.61 (+0.56%)

AZN AstraZeneca
$48.10 /

-0.25 (-0.52%)

AMED Amedisys
$254.74 /

+0.61 (+0.24%)

AFMD Affimed
$5.91 /

+0.25 (+4.42%)

ABC AmerisourceBergen
$103.12 /

+1.88 (+1.86%)

ABC AmerisourceBergen
$103.12 /

+1.88 (+1.86%)

02/09/21 Mizuho
AmerisourceBergen price target raised to $114 from $104 at Mizuho
02/08/21 Cowen
AmerisourceBergen price target raised to $150 from $145 at Cowen
02/04/21 Evercore ISI
AmerisourceBergen upgraded to Outperform after Q1 report at Evercore ISI
02/04/21 Evercore ISI
AmerisourceBergen upgraded to Outperform from In Line at Evercore ISI
AFMD Affimed
$5.91 /

+0.25 (+4.42%)

AMED Amedisys
$254.74 /

+0.61 (+0.24%)

02/23/21 Benchmark
Amedisys price target raised to $325 from $275 at Benchmark
02/08/21 Deutsche Bank
Amedisys price target raised to $340 from $275 at Deutsche Bank
01/05/21 Truist
Amedisys price target raised to $325 from $280 at Truist
11/03/20 Barclays
Amedisys price target raised to $298 from $290 at Barclays
AZN AstraZeneca
$48.10 /

-0.25 (-0.52%)

02/25/21
Fly Intel: Top five analyst upgrades
02/25/21 UBS
AstraZeneca upgraded to Buy from Neutral at UBS
02/04/21 Piper Sandler
Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler
02/01/21 BofA
BofA downgrades Moderna to Underperform, sees shares priced for 'best-case'
BNTX BioNTech
$110.06 /

+0.61 (+0.56%)

02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
01/29/21 Piper Sandler
Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
CSL Carlisle
$148.03 /

+2.725 (+1.88%)

01/26/21 Longbow
Carlisle price target raised to $160 from $150 at Longbow
01/08/21 Oppenheimer
Carlisle price target raised to $175 from $160 at Oppenheimer
11/13/20
Carlisle cut to Hold at Loop Capital on valuation
11/13/20 Loop Capital
Carlisle downgraded to Hold from Buy at Loop Capital
CVAC CureVac
$96.15 /

+1.39 (+1.47%)

01/07/21 Morgan Stanley
CureVac COVID-19 deal provides 'sentiment boost' for Bayer, says Morgan Stanley
12/10/20 Credit Suisse
CureVac downgraded to Underperform on rising valuation at Credit Suisse
12/10/20 Credit Suisse
CureVac downgraded to Underperform from Neutral at Credit Suisse
11/02/20 Piper Sandler
CureVac's positive vaccine data bodes well for Arcturus's ARCT-021, says Piper
FMS Fresenius Medical
$35.05 /

+0.49 (+1.42%)

02/26/21 JPMorgan
Fresenius Medical price target raised to EUR 52.40 from EUR 51.10 at JPMorgan
02/24/21 Truist
Fresenius Medical cut to Hold at Truist on more difficult operating backdrop
02/24/21 Truist
Fresenius Medical downgraded to Hold from Buy at Truist
02/17/21 UBS
Fresenius Medical price target lowered to EUR 72 from EUR 94 at UBS
GLPG Galapagos
$84.65 /

+1.6 (+1.93%)

02/23/21 BofA
Galapagos upgraded to Neutral from Underperform at BofA
02/23/21 BofA
Galapagos upgraded to Neutral from Underperform at BofA
02/19/21 Raymond James
Raymond James upgrades 'heavily discounted' Galapagos to Outperform
02/19/21 Raymond James
Galapagos upgraded to Outperform from Market Perform at Raymond James
GLTO Galecto
$10.81 /

+0.5301 (+5.16%)

11/23/20 SVB Leerink
SVB Leerink bullish on Galecto, initiates with an Outperform
11/23/20 SVB Leerink
Galecto initiated with an Outperform at SVB Leerink
11/23/20 Credit Suisse
Galecto initiated with an Outperform at Credit Suisse
11/23/20 BofA
Galecto initiated with a Buy at BofA
GSK GlaxoSmithKline
$33.74 /

+0.13 (+0.39%)

02/12/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,580 GBp at Morgan Stanley
02/11/21 Berenberg
GlaxoSmithKline price target lowered to 1,570 GBp from 1,720 GBp at Berenberg
02/09/21 JPMorgan
GlaxoSmithKline price target lowered to 1,300 GBp from 1,500 GBp at JPMorgan
02/08/21 UBS
GlaxoSmithKline price target lowered to 1,320 GBp from 1,450 GBp at UBS
IVA Inventiva
$16.90 /

+1.9 (+12.67%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
IPSEY Ipsen
$0.00 /

+ (+0.00%)

02/16/21 Barclays
Ipsen price target lowered to EUR 89 from EUR 96 at Barclays
01/14/21 Societe Generale
Ipsen upgraded to Buy from Hold at Societe Generale
12/08/20 Morgan Stanley
Ipsen downgraded to Equal Weight from Overweight at Morgan Stanley
12/04/20 BofA
Ipsen downgraded to Neutral from Buy at BofA
LNTH Lantheus
$19.06 /

+0.33 (+1.76%)

02/01/21
Fly Intel: Top five analyst initiations
02/01/21 SVB Leerink
SVB Leerink bullish on Lantheus, initiates with an Outperform
02/01/21 SVB Leerink
Lantheus initiated with an Outperform at SVB Leerink
12/29/20 Credit Suisse
Lantheus price target lowered to $14 from $16 at Credit Suisse
NOV NOV Inc.
$15.65 /

+0.525 (+3.47%)

01/21/21 Susquehanna
NOV Inc. price target lowered to $17 from $18 at Susquehanna
01/21/21 Wells Fargo
NOV Inc. upgraded to Overweight from Equal Weight at Wells Fargo
01/21/21 Wells Fargo
NOV Inc. upgraded to Overweight from Equal Weight at Wells Fargo
01/12/21 Citi
NOV Inc. upgraded to Buy from Neutral at Citi
NOVO Novo Group Inc
$0.00 /

+ (+0.00%)

NVS Novartis
$87.44 /

+1.42 (+1.65%)

03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
02/02/21 Morgan Stanley
Novartis price target lowered to CHF 102 from CHF 104 at Morgan Stanley
02/01/21 Truist
iRhythm price target lowered to $220 from $265 at Truist
02/01/21 Cowen
Novartis downgraded to Market Perform after 'tepid' guidance at Cowen
PHG Philips
$55.04 /

+0.54 (+0.99%)

01/26/21 Credit Suisse
Philips price target raised to EUR 45 from EUR 41 at Credit Suisse
01/26/21 JPMorgan
Philips price target raised to EUR 44.90 from EUR 44 at JPMorgan
01/26/21 UBS
Philips price target raised to EUR 54 from EUR 51 at UBS
01/25/21 Morgan Stanley
iRhythm price target raised to $288 from $227 at Morgan Stanley
SNY Sanofi
$45.90 /

+0.015 (+0.03%)

02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
02/10/21 Morgan Stanley
Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
01/19/21 UBS
Sanofi price target lowered to EUR 99 from EUR 100 at UBS
TAK Takeda Pharmaceutical
$16.97 /

+0.26 (+1.56%)

01/29/21 Morgan Stanley
Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout
12/29/20 Needham
Needham names Phathom Pharmaceuticals Top Pick for 2021
12/15/20 Needham
Phathom Pharmaceuticals price target raised to $55 from $45 at Needham
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
ZEAL Zealand Pharma
$32.71 /

+0.76 (+2.38%)

03/10/20 Morgan Stanley
Zealand Pharma EPS estimates cut at Morgan Stanley
ZEAL Zealand Pharma
$32.71 /

+0.76 (+2.38%)

SNY Sanofi
$45.90 /

+0.015 (+0.03%)

PHG Philips
$55.04 /

+0.54 (+0.99%)

NVS Novartis
$87.44 /

+1.42 (+1.65%)

NOV NOV Inc.
$15.65 /

+0.525 (+3.47%)

LNTH Lantheus
$19.06 /

+0.33 (+1.76%)

GSK GlaxoSmithKline
$33.74 /

+0.13 (+0.39%)

GLTO Galecto
$10.81 /

+0.5301 (+5.16%)

GLPG Galapagos
$84.65 /

+1.6 (+1.93%)

CSL Carlisle
$148.03 /

+2.725 (+1.88%)

AZN AstraZeneca
$48.10 /

-0.25 (-0.52%)

AMED Amedisys
$254.74 /

+0.61 (+0.24%)

ABC AmerisourceBergen
$103.12 /

+1.88 (+1.86%)

  • 28
    Jan
  • 13
    Jan
  • 29
    Oct
  • 14
    Aug
  • 23
    Jul
  • 10
    Jul
TAK Takeda Pharmaceutical
$16.97 /

+0.26 (+1.56%)

SNY Sanofi
$45.90 /

+0.015 (+0.03%)

PHG Philips
$55.04 /

+0.54 (+0.99%)

NVS Novartis
$87.44 /

+1.42 (+1.65%)

GSK GlaxoSmithKline
$33.74 /

+0.13 (+0.39%)

FMS Fresenius Medical
$35.05 /

+0.49 (+1.42%)

CVAC CureVac
$96.15 /

+1.39 (+1.47%)

BNTX BioNTech
$110.06 /

+0.61 (+0.56%)

AZN AstraZeneca
$48.10 /

-0.25 (-0.52%)

ABC AmerisourceBergen
$103.12 /

+1.88 (+1.86%)

SNY Sanofi
$45.90 /

+0.015 (+0.03%)

PHG Philips
$55.04 /

+0.54 (+0.99%)

NVS Novartis
$87.44 /

+1.42 (+1.65%)

NOV NOV Inc.
$15.65 /

+0.525 (+3.47%)

LNTH Lantheus
$19.06 /

+0.33 (+1.76%)

IVA Inventiva
$16.90 /

+1.9 (+12.67%)

GSK GlaxoSmithKline
$33.74 /

+0.13 (+0.39%)

GLTO Galecto
$10.81 /

+0.5301 (+5.16%)

GLPG Galapagos
$84.65 /

+1.6 (+1.93%)

CVAC CureVac
$96.15 /

+1.39 (+1.47%)

BNTX BioNTech
$110.06 /

+0.61 (+0.56%)

AZN AstraZeneca
$48.10 /

-0.25 (-0.52%)

AMED Amedisys
$254.74 /

+0.61 (+0.24%)

ABC AmerisourceBergen
$103.12 /

+1.88 (+1.86%)

TAK Takeda Pharmaceutical
$16.97 /

+0.26 (+1.56%)

NOV NOV Inc.
$15.65 /

+0.525 (+3.47%)

GSK GlaxoSmithKline
$33.74 /

+0.13 (+0.39%)

CVAC CureVac
$96.15 /

+1.39 (+1.47%)

BNTX BioNTech
$110.06 /

+0.61 (+0.56%)

AZN AstraZeneca
$48.10 /

-0.25 (-0.52%)

ABC AmerisourceBergen
$103.12 /

+1.88 (+1.86%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.